Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States
Satellos got a US patent for its main experimental drug and similar medicines. This protects their work and shows progress toward helping people with muscle diseases.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.